The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice
Open accessAbstract
Background The identification of the cellular and molecular pathways that mediate the development of non-alcoholic steatohepatitis is of crucial importance. Cytokines produced by liver-resident and infiltrating inflammatory cells, play a pivotal role in liver inflammation. The role of the proinflammatory cytokines IL-1α and IL-1β in steatohepatitis remains elusive. Aims & Methods We employed IL-1α and IL-1β-deficient mice and transplanted marrow cells to study the role of liver-resident and bone marrow-derived IL-1 in steatosis and its progression to steatohepatitis. Results Atherogenic diet-induced steatohepatitis in wild-type mice was associated with 16 and 4.6 folds-elevations in mRNA levels of hepatic IL-1α and IL-1β, respectively. In mice deficient in either IL-1α or IL-1β the transformation of steatosis to steatohepatitis and liver fibrosis was markedly reduced. This protective effect in IL-1α-deficient mice was noted despite increased liver cholesterol levels. Deficiency of IL-1α markedly reduced plasma serum amyloid A and steady-state levels of mRNA coding for inflammatory genes (P-selectin, CXCL1, IL-6, TNFα) as well as pro-fibrotic genes (MMP-9 and Collagen) and particularly a 50% decrease in TGFβ (p=0.004). IL-1α mRNA levels were 2 folds lower in IL-1β-deficient mice, and IL-1β transcripts were 3 folds lower in IL-1α-deficient compared to wild-type mice. Hepatic cell derived IL-1α rather than from recruited bone marrow-derived cells is required for steatohepatitis development. Conclusions These data demonstrate the critical role of IL-1α and IL-1β in the transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. Therefore, the potential of neutralizing IL-1α and/or IL-1β to inhibit development of steatohepatitis should be explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
Self-citationImmunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466
Self-citationDAMPs, PAMPs and alarmins: all we need to know about danger
Bianchi, M. E. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306164 · Cited by 2,794
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Yamaguchi, K., Yang, L., McCall, S., Huang, J., Yu, X. X., Pandey, S. K., Bhanot, S., Monia, B. P., Li, Y.-X., & Diehl, A. M. (2007) · Hepatology · doi:10.1002/hep.21655 · Cited by 1,015
The Sterile Inflammatory Response
Rock, K. L., Latz, E., Ontiveros, F., & Kono, H. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101311 · Cited by 865
Toll-Like Receptor 9 Promotes Steatohepatitis by Induction of Interleukin-1β in Mice
Miura, K., Kodama, Y., Inokuchi, S., Schnabl, B., Aoyama, T., Ohnishi, H., Olefsky, J. M., Brenner, D. A., & Seki, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.03.052 · Cited by 741
Horai, R., Asano, M., Sudo, K., Kanuka, H., Suzuki, M., Nishihara, M., Takahashi, M., & Iwakura, Y. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.9.1463 · Cited by 611
Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis
Marí, M., Caballero, F., Colell, A., Morales, A., Caballeria, J., Fernandez, A., Enrich, C., Fernandez-Checa, J. C., & García-Ruiz, C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.07.006 · Cited by 608
Cited by
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
Targeting hepatic macrophages to treat liver diseases
Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.026 · Cited by 1,003
Inflammation: The Common Pathway of Stress-Related Diseases
Liu, Y.-Z., Wang, Y.-X., & Jiang, C.-L. (2017) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2017.00316 · Cited by 800
Pathogenesis of liver cirrhosis
Zhou, W.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7312 · Cited by 627
Host Responses in Tissue Repair and Fibrosis
Duffield, J. S., Lupher, M., Thannickal, V. J., & Wynn, T. A. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163930 · Cited by 624
From NAFLD to NASH to cirrhosis—new insights into disease mechanisms
Wree, A., Broderick, L., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.149 · Cited by 609
Inflammasome activation and function in liver disease
Szabo, G., & Petrasek, J. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.94 · Cited by 597
IL-1α and IL-1β Recruit Different Myeloid Cells and Promote Different Stages of Sterile Inflammation
Rider, P., Carmi, Y., Guttman, O., Braiman, A., Cohen, I., Voronov, E., White, M. R., Dinarello, C. A., & Apte, R. N. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102048 · Cited by 522
Self-citationMack, M. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.11.010 · Cited by 514
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Tilg, H., Adolph, T. E., Dudek, M., & Knolle, P. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00501-9 · Cited by 507
Inflammasomes in liver diseases
Szabo, G., & Csak, T. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.03.035 · Cited by 495
NLRP3 inflammasome activation is required for fibrosis development in NAFLD
Wree, A., McGeough, M. D., Peña, C. A., Schlattjan, M., Li, H., Inzaugarat, M. E., Messer, K., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1170-1 · Cited by 486
“They found that selective deficiency in IL-1β in liver parenchymal cells, but not in bone-marrow-derived cells, protected mice from diet-induced steatohepatitis and fibrosis [16].”
The NLRP3 inflammasome: Mechanism of action, role in disease and therapies
Wang, L., & Hauenstein, A. V. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100889 · Cited by 426
Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade
Tilg, H., Adolph, T. E., & Moschen, A. R. (2021) · Hepatology · doi:10.1002/hep.31518 · Cited by 426
Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation
Peverill, W., Powell, L., & Skoien, R. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15058591 · Cited by 376
Cytokine mediated tissue fibrosis
Borthwick, L. A., Wynn, T. A., & Fisher, A. J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.09.014 · Cited by 375
Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease
Miura, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7381 · Cited by 355
Stojsavljević, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i48.18070 · Cited by 325
Tilg, H., Moschen, A. R., & Szabo, G. (2016) · Hepatology · doi:10.1002/hep.28456 · Cited by 319
NLRP3 at the interface of metabolism and inflammation
Haneklaus, M., & O'Neill, L. A. J. (2015) · Immunological Reviews · doi:10.1111/imr.12285 · Cited by 294
Gardner, S. E., Humphry, M., Bennett, M. R., & Clarke, M. C. H. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305896 · Cited by 285
Role of the Inflammasome in Liver Disease
de Carvalho Ribeiro, M., & Szabo, G. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-032521-102529 · Cited by 277
Macrophage autophagy protects against liver fibrosis in mice
Lodder, J., Denaës, T., Chobert, M.-N., Wan, J., El-Benna, J., Pawlotsky, J.-M., Lotersztajn, S., & Teixeira-Clerc, F. (2015) · Autophagy · doi:10.1080/15548627.2015.1058473 · Cited by 266
Hendrikx, T., Porsch, F., Kiss, M. G., Rajcic, D., Papac-Miličević, N., Hoebinger, C., Goederle, L., Hladik, A., Shaw, L. E., Horstmann, H., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.004 · Cited by 220
Inflammasomes in liver fibrosis
Alegre, F., Pelegrin, P., & Feldstein, A. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1601350 · Cited by 176
Rider, P., Carmi, Y., Voronov, E., & Apte, R. N. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.005 · Cited by 155
Self-citationInzaugarat, M. E., Johnson, C. D., Holtmann, T. M., McGeough, M. D., Trautwein, C., Papouchado, B. G., Schwabe, R., Hoffman, H. M., Wree, A., & Feldstein, A. E. (2019) · Hepatology · doi:10.1002/hep.30252 · Cited by 148
“(27) Moreover, mice deficient in Casp-1, ASC, and NLRP3 have been shown to exhibit a protective effect on fibrosis development in several experimental murine models, as evidenced by decreased TGF-β and Col1a1 expression, and reduced serum levels of TIMP1 and hyaluronic acid.(13,30-33) In contrast, persistent global ac…”
Pawlak, M., Baugé, E., Bourguet, W., De Bosscher, K., Lalloyer, F., Tailleux, A., Lebherz, C., Lefebvre, P., & Staels, B. (2014) · Hepatology · doi:10.1002/hep.27297 · Cited by 141
Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities
Idalsoaga, F., Kulkarni, A. V., Mousa, O. Y., Arrese, M., & Arab, J. P. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00448 · Cited by 136
Mia, M. M., Boersema, M., & Bank, R. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091559 · Cited by 109
Kaufmann, B., Kui, L., Reca, A., Leszczynska, A., Kim, A. D., Booshehri, L. M., Wree, A., Friess, H., Hartmann, D., Broderick, L., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.06.007 · Cited by 51
“A central role in liver injury, NASH, and fibrogenesis was demonstrated for NLRP3 inflammasome-dependent cleavage of caspase 1 and IL1b.(9,10,13,23-25) Similarly, TNF-a was shown to be a key modulator in both liver inflammation and fibrosis.”
BackgroundMeyer, M., Schwärzler, J., Jukic, A., & Tilg, H. (2024) · Biomolecules · doi:10.3390/biom14040476 · Cited by 50
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)?
Tilg, H., Effenberger, M., & Adolph, T. E. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1681397 · Cited by 28
Metadata
- Authors
- Kamari, Y., Shaish, A., Vax, E., Shemesh, S., Kandel-Kfir, M., Arbel, Y., Olteanu, S., Barshack, I., Dotan, S., Voronov, E., Dinarello, C. A., Apte, R. N., & Harats, D.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2011-11
- Volume
- 55
- Issue
- 5
- Pages
- 1086-1094
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2144030722
- Cited by
- 287
- References
- 37
- FWCI
- 11.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.